The University of Chicago Header Logo

Connection

Yusuke Nakamura to Biomarkers, Tumor

Back to Details
This is a "connection" page, showing publications Yusuke Nakamura has written about Biomarkers, Tumor.
Yusuke Nakamura
Connection Strength
3.131
Biomarkers, Tumor
  1. The GALNT6-LGALS3BP axis promotes breast cancer cell growth. Int J Oncol. 2020 Feb; 56(2):581-595.
    View in: PubMed
    Score: 0.339
  2. From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma. Gen Thorac Cardiovasc Surg. 2008 Feb; 56(2):43-53.
    View in: PubMed
    Score: 0.150
  3. Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer. Int J Oncol. 2006 Sep; 29(3):567-75.
    View in: PubMed
    Score: 0.135
  4. Characterization of SEZ6L2 cell-surface protein as a novel prognostic marker for lung cancer. Cancer Sci. 2006 Aug; 97(8):737-45.
    View in: PubMed
    Score: 0.134
  5. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res. 2005 Oct 15; 65(20):9176-84.
    View in: PubMed
    Score: 0.127
  6. Hypoxia-inducible protein 2 (HIG2), a novel diagnostic marker for renal cell carcinoma and potential target for molecular therapy. Cancer Res. 2005 Jun 01; 65(11):4817-26.
    View in: PubMed
    Score: 0.124
  7. ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res. 2004 Dec 15; 10(24):8363-70.
    View in: PubMed
    Score: 0.120
  8. Gene expression patterns as marker for 5-year postoperative prognosis of primary breast cancers. J Cancer Res Clin Oncol. 2004 Sep; 130(9):537-45.
    View in: PubMed
    Score: 0.116
  9. Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer. Cancer Sci. 2021 Jan; 112(1):454-464.
    View in: PubMed
    Score: 0.090
  10. Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer. Breast Cancer Res Treat. 2020 Apr; 180(2):331-341.
    View in: PubMed
    Score: 0.086
  11. Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma. Mol Cancer Ther. 2019 03; 18(3):507-516.
    View in: PubMed
    Score: 0.080
  12. Clinical significance of T cell clonality and expression levels of immune-related genes in endometrial cancer. Oncol Rep. 2017 May; 37(5):2603-2610.
    View in: PubMed
    Score: 0.070
  13. Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. J Exp Clin Cancer Res. 2017 02 28; 36(1):36.
    View in: PubMed
    Score: 0.070
  14. Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor. Oncotarget. 2016 Apr 05; 7(14):18171-82.
    View in: PubMed
    Score: 0.066
  15. Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies. J Natl Cancer Inst. 2014 Dec 08; 107(2).
    View in: PubMed
    Score: 0.060
  16. Plasma low-molecular-weight proteome profiling identified neuropeptide-Y as a prostate cancer biomarker polypeptide. J Proteome Res. 2013 Oct 04; 12(10):4497-506.
    View in: PubMed
    Score: 0.055
  17. RASEF is a novel diagnostic biomarker and a therapeutic target for lung cancer. Mol Cancer Res. 2013 Aug; 11(8):937-51.
    View in: PubMed
    Score: 0.054
  18. The transcription factor Sp3 regulates the expression of a metastasis-related marker of sarcoma, actin filament-associated protein 1-like 1 (AFAP1L1). PLoS One. 2013; 8(1):e49709.
    View in: PubMed
    Score: 0.052
  19. Proteomic characterization of ovarian cancers identifying annexin-A4, phosphoserine aminotransferase, cellular retinoic acid-binding protein 2, and serpin B5 as histology-specific biomarkers. Cancer Sci. 2012 Apr; 103(4):747-55.
    View in: PubMed
    Score: 0.049
  20. Characterization of an Opa interacting protein 5 involved in lung and esophageal carcinogenesis. Cancer Sci. 2012 Mar; 103(3):577-86.
    View in: PubMed
    Score: 0.049
  21. Chondrolectin is a novel diagnostic biomarker and a therapeutic target for lung cancer. Clin Cancer Res. 2011 Dec 15; 17(24):7712-22.
    View in: PubMed
    Score: 0.048
  22. Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer. Mol Cancer. 2011 May 28; 10:65.
    View in: PubMed
    Score: 0.047
  23. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci. 2011 Jul; 102(7):1298-305.
    View in: PubMed
    Score: 0.047
  24. A comprehensive peptidome profiling technology for the identification of early detection biomarkers for lung adenocarcinoma. PLoS One. 2011 Apr 12; 6(4):e18567.
    View in: PubMed
    Score: 0.046
  25. Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy. Cancer Res. 2010 Jul 01; 70(13):5326-36.
    View in: PubMed
    Score: 0.044
  26. Activation of WD repeat and high-mobility group box DNA binding protein 1 in pulmonary and esophageal carcinogenesis. Clin Cancer Res. 2010 Jan 01; 16(1):226-39.
    View in: PubMed
    Score: 0.042
  27. Serum REG4 level is a predictive biomarker for the response to preoperative chemoradiotherapy in patients with pancreatic cancer. Pancreas. 2009 Oct; 38(7):791-8.
    View in: PubMed
    Score: 0.042
  28. Targeted serum glycoproteomics for the discovery of lung cancer-associated glycosylation disorders using lectin-coupled ProteinChip arrays. Proteomics. 2009 Apr; 9(8):2182-92.
    View in: PubMed
    Score: 0.040
  29. Identification of C2orf18, termed ANT2BP (ANT2-binding protein), as one of the key molecules involved in pancreatic carcinogenesis. Cancer Sci. 2009 Mar; 100(3):457-64.
    View in: PubMed
    Score: 0.040
  30. Over expression of hypoxia-inducible protein 2, hypoxia-inducible factor-1alpha and nuclear factor kappaB is putatively involved in acquired renal cyst formation and subsequent tumor transformation in patients with end stage renal failure. J Urol. 2008 Aug; 180(2):481-5.
    View in: PubMed
    Score: 0.038
  31. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin. Lung Cancer. 2008 Oct; 62(1):45-54.
    View in: PubMed
    Score: 0.038
  32. Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res. 2007 Dec 15; 67(24):11601-11.
    View in: PubMed
    Score: 0.037
  33. Activation of KIF4A as a prognostic biomarker and therapeutic target for lung cancer. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6624-31.
    View in: PubMed
    Score: 0.037
  34. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci. 2007 Nov; 98(11):1803-8.
    View in: PubMed
    Score: 0.037
  35. Comparative profiling of serum glycoproteome by sequential purification of glycoproteins and 2-nitrobenzensulfenyl (NBS) stable isotope labeling: a new approach for the novel biomarker discovery for cancer. J Proteome Res. 2007 Sep; 6(9):3475-83.
    View in: PubMed
    Score: 0.036
  36. Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res. 2007 Mar 15; 67(6):2517-25.
    View in: PubMed
    Score: 0.035
  37. Genome-wide gene expression profiles of clear cell renal cell carcinoma: identification of molecular targets for treatment of renal cell carcinoma. Int J Oncol. 2006 Oct; 29(4):799-827.
    View in: PubMed
    Score: 0.034
  38. Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4. Cancer Sci. 2006 Nov; 97(11):1191-7.
    View in: PubMed
    Score: 0.034
  39. Analysis of gene-expression profiles in testicular seminomas using a genome-wide cDNA microarray. Int J Oncol. 2003 Dec; 23(6):1615-35.
    View in: PubMed
    Score: 0.028
  40. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun. 2003 Jun 20; 306(1):16-25.
    View in: PubMed
    Score: 0.027
  41. Identification of a novel human gene, ZFP91, involved in acute myelogenous leukemia. Int J Oncol. 2003 Jun; 22(6):1217-23.
    View in: PubMed
    Score: 0.027
  42. Tumor-Informed Approach Improved ctDNA Detection Rate in Resected Pancreatic Cancer. Int J Mol Sci. 2022 Sep 29; 23(19).
    View in: PubMed
    Score: 0.026
  43. Isolation and characterization of a novel human gene, VANGL1, as a therapeutic target for hepatocellular carcinoma. Int J Oncol. 2002 Jun; 20(6):1173-8.
    View in: PubMed
    Score: 0.025
  44. Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer. Cancer Sci. 2022 May; 113(5):1808-1820.
    View in: PubMed
    Score: 0.025
  45. Clinical implementation and current advancement of blood liquid biopsy in cancer. J Hum Genet. 2021 Sep; 66(9):909-926.
    View in: PubMed
    Score: 0.023
  46. miR-125b-1 and miR-378a are predictive biomarkers for the efficacy of vaccine treatment against colorectal cancer. Cancer Sci. 2017 Nov; 108(11):2229-2238.
    View in: PubMed
    Score: 0.018
  47. Clinical and histopathological characteristics of patients with prostate cancer in the BioBank Japan project. J Epidemiol. 2017 Mar; 27(3S):S65-S70.
    View in: PubMed
    Score: 0.017
  48. Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer. Oncotarget. 2016 Mar 22; 7(12):13621-33.
    View in: PubMed
    Score: 0.016
  49. VAV3 mediates resistance to breast cancer endocrine therapy. Breast Cancer Res. 2014 May 28; 16(3):R53.
    View in: PubMed
    Score: 0.014
  50. A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome. J Transl Med. 2014 Mar 10; 12:63.
    View in: PubMed
    Score: 0.014
  51. Soluble MICA and a MICA variation as possible prognostic biomarkers for HBV-induced hepatocellular carcinoma. PLoS One. 2012; 7(9):e44743.
    View in: PubMed
    Score: 0.013
  52. The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6. Cancer Prev Res (Phila). 2011 Dec; 4(12):2051-61.
    View in: PubMed
    Score: 0.012
  53. Identification of Epstein-Barr virus-induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer. Clin Cancer Res. 2011 Oct 01; 17(19):6272-86.
    View in: PubMed
    Score: 0.012
  54. A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cells. Cancer Sci. 2011 Apr; 102(4):697-705.
    View in: PubMed
    Score: 0.011
  55. Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism. Cancer Res. 2009 Oct 15; 69(20):8133-40.
    View in: PubMed
    Score: 0.010
  56. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma. J Gastroenterol. 2010; 45(1):52-9.
    View in: PubMed
    Score: 0.010
  57. Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res. 2009 Aug 15; 69(16):6694-703.
    View in: PubMed
    Score: 0.010
  58. Frequent decreased expression of candidate tumor suppressor gene, DEC1, and its anchorage-independent growth properties and impact on global gene expression in esophageal carcinoma. Int J Cancer. 2008 Feb 01; 122(3):587-94.
    View in: PubMed
    Score: 0.009
  59. Fibroblast growth factor receptor 1 oncogene partner as a novel prognostic biomarker and therapeutic target for lung cancer. Cancer Sci. 2007 Dec; 98(12):1902-13.
    View in: PubMed
    Score: 0.009
  60. Increased expression of insulin-like growth factor-II messenger RNA-binding protein 1 is associated with tumor progression in patients with lung cancer. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):434-42.
    View in: PubMed
    Score: 0.009
  61. Molecular target therapy for synovial sarcoma. Future Oncol. 2005 Dec; 1(6):805-12.
    View in: PubMed
    Score: 0.008
  62. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice. Clin Cancer Res. 2004 Dec 15; 10(24):8630-40.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.